Role of spinal P2Y\textsubscript{6} and P2Y\textsubscript{11} receptors in neuropathic pain in rats: possible involvement of glial cells

Paulino Barragán-Iglesias\textsuperscript{1}, Jorge Baruch Pineda-Farias\textsuperscript{1}, Claudia Cervantes-Durán\textsuperscript{1}, Mariana Bravo-Hernández\textsuperscript{1}, Héctor Isaac Rocha-González\textsuperscript{2}, Janet Murbartíán\textsuperscript{1} and Vinicio Granados-Soto\textsuperscript{1*}

Abstract

Background: The participation of spinal P2X receptors in neuropathic pain is well recognized. However, the role of P2Y receptors has been less studied. The purpose of this study was to investigate the contribution of spinal P2Y\textsubscript{6,11} receptors following peripheral nerve damage induced by spinal nerve ligation. In addition, we determined the expression of P2Y\textsubscript{6,11} receptors in the dorsal spinal cord in presence of the selective P2Y\textsubscript{6,11} receptor antagonists. Furthermore, we evaluated the participation of spinal microglia and astrocytes in the pronociceptive role of P2Y\textsubscript{6,11} receptors.

Results: Spinal administration of the selective P2Y\textsubscript{6} (MRS2578, 10–100 \textmu M) and P2Y\textsubscript{11} (NF340, 0.3–30 \textmu M) receptor antagonists reduced tactile allodynia in spinal nerve ligated rats. Nerve injury increased the expression of P2Y\textsubscript{6,11} receptors at 7, 14 and 21 days after injury. Furthermore, intrathecal administration of MRS2578 (100 \textmu M/day) and NF340 (30 \textmu M/day) for 3 days significantly reduced spinal nerve injury-induced increase in P2Y\textsubscript{6,11} receptors expression, respectively. Spinal treatment (on day 14 after injury) with minocycline (100 \textmu g/day) or fluorocitrate (1 nmol/day) for 7 days reduced tactile allodynia and spinal nerve injury-induced up-regulation in Iba-1 and GFAP, respectively. In addition, minocycline reduced nerve injury-induced up-regulation in P2Y\textsubscript{6,11} receptors whereas that fluorocitrate diminished P2Y\textsubscript{11}, but not P2Y\textsubscript{6} receptors up-regulation. Intrathecal treatment (on day 21 after injury) with the selective P2Y\textsubscript{6} (PSB0474, 3–30 \mu M) and P2Y\textsubscript{11} (NF546, 1–10 \mu M) receptor agonists produced remarkable tactile allodynia in nerve ligated rats previously treated with minocycline or fluorocitrate for 7 days.

Conclusions: Our data suggest that spinal P2Y\textsubscript{6} is present in spinal microglia while P2Y\textsubscript{11} receptors are present in both spinal microglia and astrocytes, and both receptors are up-regulated in rats subjected to spinal nerve injury. In addition, our data suggest that the spinal P2Y\textsubscript{6} and P2Y\textsubscript{11} receptors participate in the maintenance of neuropathic pain.

Keywords: Astrocytes, Microglia, Neuropathic pain, P2Y\textsubscript{6} receptors, P2Y\textsubscript{11} receptors, Spinal cord

Background

ATP (adenosine triphosphate) is released from primary afferents following peripheral tissue/nerve damage producing pain [1,2]. The pronociceptive role of ATP in nociception is well characterized [3-8]. This effect has been associated with the activation of the P2X family receptors expressed in dorsal root ganglion [9-12], satellite glial cells [13,14], spinal dorsal horn [15-17] and microglia/astrocytes [16,18,19]. Following nerve damage, spinal microglia and astrocytes proliferate and up-regulate specific protein markers like ionized calcium-binding adapter molecule-1 (Iba-1) and glial fibrillary acidic protein (GFAP), respectively [20,21]. It is thought that these changes are involved in neuropathic pain as activated microglia and astrocytes have the ability to modify and modulate neuronal firing and to release pro- and anti-inflammatory molecules. Importantly, spinal microglia is activated by ATP through P2X\textsubscript{4} and P2X\textsubscript{7} receptors leading to release of pro-inflammatory cytokines (interleukin-1\textbeta [IL-1\textbeta]), tumor necrosis factor \alpha [TNF\textalpha],...
interleukin-6 (IL-6), chemokines (CCL-2, fractalkine) and neurotrophic factors (brain derived neurotrophic factor [BDNF]), among others, to produce central sensitization [22–24].

In comparison to P2X receptors, the contribution of P2Y receptors to neuropathic pain has been less studied. At the moment, there is limited evidence to suggest that P2Y receptors play a role in neuropathic pain. However, data have shown that P2Y1 receptors mRNA is up-regulated in rat dorsal root ganglion neurons after peripheral axotomy of the sciatic nerve [25]. Likewise, P2Y1 and P2Y2 receptors mRNAs are up-regulated in peripheral axotomy of the sciatic nerve [25]. P2Y receptors might also be involved in spinal microglia activation during neuropathic pain conditions. In this sense, P2Y12 receptors are up-regulated in spinal microglia after peripheral nerve injury [27]. Moreover, P2Y6, P2Y13 and P2Y14 mRNAs are up-regulated in microglia in the ipsilateral spinal cord following nerve injury [28]. Furthermore, recent evidence suggests that some P2Y receptors are expressed in satellite glial cells and astrocytes and they contribute to neuropathic pain following nerve damage [29].

Due to the limited information about the participation of P2Y receptors in neuropathic pain, we decided to study the role of spinal P2Y6 and P2Y11 receptors in the maintenance of neuropathic pain in the rat by pharmacological and molecular methods. Our data suggest that spinal P2Y6 is present in spinal microglia while P2Y11 receptors are present in both spinal microglia and astrocytes, and both receptors are up-regulated in rats subjected to spinal nerve injury. In addition, our data suggest that the spinal P2Y6 and P2Y11 receptors participate in the maintenance of neuropathic pain.

Results

Antiallodynic effects of selective P2Y6 (MRS2578) and P2Y11 (NF340) receptor antagonists in rats

Spinal nerve injury produced tactile allodynia in the ipsilateral hind paw, which was evident by a significant decrease in the 50% paw withdrawal threshold response as compared to the naive group (Figure 1A/C). As expected, sham surgery did not change the 50% withdrawal threshold response on the ipsilateral side as previously reported by our group [30]. Furthermore, intrathecal administration of vehicle did not affect tactile allodynia induced by spinal nerve ligation (Figure 1A/C). In marked contrast, the spinal administration of the selective P2Y6 (MRS2578, Figure 1A) and P2Y11 (NF340, Figure 1C) receptor antagonists produced an antiallodynic effect in the spinal nerve injured rats. The maximal antiallodynic effect in both cases was reached in about 1 h and then decayed gradually in about 6 h. However, MRS2578 had a greater peak effect than NF340, although the effect of the later decayed more slowly. MRS2578 (10–100 μM, Figure 1B) and NF340 (0.3–30 μM, Figure 1D) reversed significantly (p < 0.05) and dose-dependently tactile allodynia in the spinal nerve injured rats.

Expression of P2Y6 and P2Y11 receptors in spinal nerve injured rats: effects of MRS2578 and NF340

Western blot analysis showed bands of about 36 and 75 kDa for P2Y6 (Figure 2A) and P2Y11 (Figure 2B) receptors at the ipsilateral dorsal spinal cord, respectively. Spinal nerve ligation produced a significant (p < 0.05) increase in the expression of P2Y6 and P2Y11 receptors at 7 and 14 days (Figure 2A/B), as well as 21 days after nerve injury (Additional file 1: Figure S1). No significant (p > 0.05) increase of P2Y6 (Additional file 2: Figure S2A) and P2Y11 (Additional file 2: Figure S2B) receptors expression was observed in the contralateral dorsal spinal cord. There were no immunoreactive bands for both receptors when the primary antibodies were pre-adsorbed with the corresponding antigenic peptides (Figure 2C).

Repeated intrathecal administration (starting on day 12 after nerve injury) of the selective P2Y6 (MRS2578, 100 μM/12 h for 3 days) and P2Y11 (NF340, 30 μM/12 h for 3 days) receptor antagonists, but not vehicle, significantly (p < 0.05) reversed spinal nerve ligation-induced increase in P2Y6 (Figure 3A) and P2Y11 (Figure 3B) receptors expression in the dorsal spinal cord on day 14 after nerve injury.

Effect of minocycline or fluorocitrate on tactile allodynia, glial markers, and P2Y6,11 receptors expression

Spinal nerve injury produced tactile allodynia as well as a significant (p < 0.05) increase in the expression of microglia and astrocytes markers Iba-1 (Figure 4A) and GFAP (Figure 4C), respectively, 21 days later. This increase was only evident in the ipsilateral, but not contralateral, section of the dorsal spinal cord (Figure 4B/D).

Once established tactile alldynia (14 days after nerve injury), repeated intrathecal treatment with minocycline (100 μg/day for 7 days, Figure 4E) or fluorocitrate (1 nmol/day for 7 days, Figure 4F), but not vehicle, reduced tactile allodynia in the spinal nerve ligated rats and diminished the increase in microglia and astrocytes markers Iba-1 (Figure 4A) and GFAP (Figure 4C) in the ipsilateral, but not contralateral, section of the dorsal spinal cord (Figure 4B/D). Moreover, repeated intrathecal administration of minocycline significantly (p < 0.05) reduced spinal nerve injury-induced increase in P2Y6 (Figure 5A) and P2Y11 (Figure 5B) expression in rats. In contrast, repeated intrathecal injection of fluorocitrate only diminished the increase of P2Y11 (Figure 5D), but not P2Y6 (Figure 5C), receptors expression in the same schedule.
Effect of selective P2Y\textsubscript{6} (PSB0474) and P2Y\textsubscript{11} (NF546) receptor agonists in spinal nerve injured rats pre-treated with minocycline or fluorocitrate

Once established tactile allodynia (14 days), repeated intrathecal treatment with minocycline (100 μg/day for 7 days, Additional file 3: Figure S3A/B) or fluorocitrate (1 nmol/day for 7 days, Additional file 3: Figures S3C/D) reversed spinal nerve injury-induced tactile allodynia. On this condition, a bolus intrathecal injection with the selective P2Y\textsubscript{6} (PSB0474, 3–30 μM; Additional file 3: Figure S3A/C) and P2Y\textsubscript{11} (NF546, 1–10 μM; Additional file 3: Figure S3B/D) receptor agonists produced a remarkable and long-lasting tactile allodynia in the rats pretreated with minocycline or fluorocitrate. In contrast, intrathecal administration of vehicles did not modify the withdrawal threshold (Additional file 3: Figure S3A-D).

Discussion

This study demonstrates that intrathecal administration of MRS2578 and NF340 partially reverses spinal nerve injury-induced tactile allodynia. Since these drugs are selective P2Y\textsubscript{6} [31] and P2Y\textsubscript{11} [32] receptor antagonists, respectively, our data suggest that both spinal receptors participate in the maintenance of neuropathic pain induced by spinal nerve injury. Our results agree with a previous report showing that intrathecal administration of MRS2578 suppresses spared nerve injury-induced mechanical allodynia [28], suggesting that spinal P2Y\textsubscript{6} receptors participate in

Figure 1 Intrathecal injection of the selective P2Y\textsubscript{6,11} receptor antagonists reverses tactile allodynia. Time course of the antiallodynic effects of the selective P2Y\textsubscript{6} (MRS2578, panel A) and P2Y\textsubscript{11} (NF340, panel C) receptor antagonists in rats submitted to spinal nerve injury. Data are expressed as mean ± S.E.M. for 6 animals. Withdrawal threshold was assessed 14 days after spinal nerve injury. Dose–response curves of the antiallodynic effect of MRS2578 (10–100 μM, panel B) and NF340 (0.3–30 μM, panel D). Data are expressed as the 50% threshold withdrawal against time curve (AUC). * Significantly different from the vehicle (Veh) group (\(p < 0.05\)), as determined by analysis of variance followed by the Student-Newman-Keuls test.

N: Naive.
**Figure 2** Spinal nerve injury enhances the expression of P2Y_{6,11} receptors. Western blot analysis of the P2Y_{6} (panel A) and P2Y_{11} (panel B) receptors expression in the ipsilateral dorsal spinal cord obtained from naïve and spinal nerve injured (SNL) rats. The primary antibody for P2Y_{6} and P2Y_{11} were pre-adsorbed with the corresponding antigenic peptide (+P, panel C). Data were normalized against β-actin and are expressed as the mean ± S.E.M. of 3 independent rats. *Significantly (p < 0.05) different from the naïve (N) group, as determined by one-way analysis of variance followed by the Student-Newman-Keuls test.

**Figure 3** P2Y_{6,11} receptor antagonists prevent enhanced expression of P2Y_{6,11} receptors. Effect of the repeated intrathecal administration of MRS2578 (panel A) and NF340 (panel B) in spinal nerve injury-induced increase in P2Y_{6} and P2Y_{11} expression in the ipsilateral dorsal spinal cord. Data were normalized against β-actin and are expressed as the mean ± S.E.M. of 3 independent rats. *Significantly (p < 0.05) different from the naïve (N) group and # significantly (p < 0.05) different from the spinal nerve ligated (SNL) group, as determined by one-way analysis of variance followed by the Student-Newman-Keuls test.
Figure 4: Spinal nerve injury increases the expression of Iba-1 and GFAP: Blockade by minocycline or fluorocitrate. Effect of the repeated intrathecal administration of minocycline (Mino, panel A and B) or fluorocitrate (Fluo, panel C and D) in spinal nerve injury-induced increased expression of Iba-1 and GFAP in the ipsilateral (IL) and contralateral (CL) dorsal spinal cord. Minocycline (panel E) and fluorocitrate (panel F) also reduced tactile allodynia in spinal nerve ligated rats. Data were normalized against β-actin and are expressed as the mean ± S.E.M. of 3 independent rats. * Significantly ($p < 0.05$) different from the sham (S) or naïve (N) groups and # significantly ($p < 0.05$) different from the spinal nerve ligated (SNL) group, as determined by one-way analysis of variance followed by the Student-Newman-Keuls test.
the maintenance of neuropathic pain. However, our data disagree with other study demonstrating that P2Y6 receptors play an antinociceptive role as intrathecal uridine diphosphate (UDP) administration (endogenous agonist) shows antiallodynic effects after partial sciatic nerve ligation [33]. This discrepancy could be explained on the basis of the used P2Y6 receptor agonist selectivity as UDP also activates the P2Y14 receptor with higher affinity than for P2Y6 receptors [34]. In our study we demonstrated that intrathecal administration of the selective P2Y6 (PSB0474) and P2Y11 (NF546) receptor agonists produces long-lasting tactile alldynia which argues against the antinociceptive effect of spinal P2Y6 receptors. Regarding NF340, this seems to be the first report demonstrating the

Figure 5 Spinal nerve injury increases the expression of P2Y6 and P2Y11: Blockade by minocycline or fluorocitrate. Effect of the repeated intrathecal administration of minocycline (Mino, panel A and B) or fluorocitrate (Fluo, panel C and D) in spinal nerve injury-induced increased expression of P2Y6 and P2Y11 receptors in the ipsilateral dorsal spinal cord. Data were normalized against β-actin and are expressed as the mean ± S.E.M. of 3 independent rats. * Significantly (p < 0.05) different from the naïve (N) group and # significantly (p < 0.05) different from the spinal nerve ligated (SNL) group, as determined by one-way analysis of variance followed by the Student-Newman-Keuls test.
antinociceptive effect of this compound suggesting that spinal P2Y<sub>11</sub> receptors play an important role in the maintenance of neuropathic pain. The contribution of P2Y<sub>6</sub> receptors seems to be different from that of P2Y<sub>11</sub> receptors as the P2Y<sub>6</sub> receptor antagonist produced a peak in the antiallodynic effect in about 1–2 h and then decayed rapidly. In contrast, the P2Y<sub>11</sub> receptor antagonist produced a modest but sustained antiallodynic effect. This discrepancy could be due to differences in the pharmacokinetics or pharmacodynamics of the tested drugs. Taken together, our data suggest the participation of spinal P2Y<sub>6,11</sub> receptors in the maintenance of neuropathic pain.

In support to our pharmacological study, we demonstrated by western blot that P2Y<sub>6,11</sub> receptors are expressed in the dorsal spinal cord of naïve rats. Previous studies indicate that P2Y<sub>6</sub> receptor mRNA is found in rat microglia [35]. On the contrary, P2Y<sub>11</sub> receptors have only been described in humans. Currently there are no reports of a cloned P2Y<sub>11</sub> receptor in rats. However, this receptor has been recently reported in epithelial cells [36], primary glial cells [37], lacrimal glands [38], neutrophils [39], and brain [38] of rats. Thus, our data suggest that the P2Y<sub>6</sub> receptor is expressed and completely functional in the spinal cord. In addition, our results suggest the presence of a P2Y<sub>11,12</sub>-like receptor in the rat spinal cord. Besides their presence in naïve animals, P2Y<sub>6,11</sub> receptors expression in the ipsilateral dorsal spinal cord was up-regulated at 7 and 14 days after spinal nerve ligation. These results partially agree with a previous study showing that P2Y<sub>6</sub> receptor mRNA is up-regulated in the ipsilateral spinal cord at 3 days following peripheral nerve injury [28]. This time difference may be due to the neuropathic pain model or the method used to quantify the expression of the P2Y<sub>6</sub> receptor (PCR versus WB). In the case of P2Y<sub>11</sub> receptors, this is the first report about their increased expression. To further reinforce the participation of spinal P2Y<sub>6,11</sub> receptors in the maintenance of neuropathic pain in rats, we demonstrated that intrathecal administration of the P2Y<sub>6,11</sub> receptor antagonists reverses spinal nerve injury-induced tactile allodynia and P2Y<sub>6,11</sub> receptors up-regulation. Admittedly, the mechanisms for the suppressive effects of P2Y<sub>6,11</sub> receptor antagonists on the up-regulation of these receptors in the dorsal spinal cord after nerve injury are unclear. However, it is likely that blockade of both receptors may lead to a fall in central sensitization that then could promote the reduction in P2Y<sub>6,11</sub> receptors expression. Clearly, further experiments which fall beyond the scope of our study will be required to confirm our suggestion.

It is accepted that spinal microglia and astrocytes release several pro-inflammatory mediators in the dorsal horn following nerve damage [22,24]. We confirmed the participation of microglia and astrocytes by showing that the ipsilateral, but not contralateral, spinal Iba-1 and GFAP are up-regulated in spinal nerve injured rats and this up-regulation is prevented by repeated administration of intrathecal minocycline or fluorocitrate, respectively. More important, spinal nerve injury increased expression of P2Y<sub>6,11</sub> receptors in the dorsal spinal cord whereas that treatment with minocyline reduced spinal nerve damage-induced P2Y<sub>6,11</sub> receptors enhanced expression. Thus, our data seem to point out that spinal P2Y<sub>6,11</sub> receptors are present in activated microglia and they participate in the maintenance of neuropathic pain in the rat. In support of this, Kobayashi and coworkers reported the enhanced presence of P2Y<sub>6,13,14</sub> receptors mRNA in spinal microglia following peripheral nerve injury [28]. Furthermore, intrathecal administration of the microglial p-38 MAPK inhibitor SB203580 suppressed spinal nerve injury-induced increase of P2Y<sub>6</sub> mRNA suggesting that activated microglia leads to an enhanced expression of P2Y<sub>6</sub> receptors and neuropathic pain [28].

We showed that fluorocitrate reduces spinal P2Y<sub>11</sub>, but not P2Y<sub>6</sub>, receptors up-regulation suggesting that activated astrocytes are over-expressing P2Y<sub>11</sub> receptors and this phenomenon contributes to maintenance of neuropathic pain. In support of this, P2Y<sub>11</sub> receptors have been found in astrocytes [37]. However, the fact that intrathecal administration of selective agonists of the P2Y<sub>6,11</sub> receptors produced tactile allodynia once microglia and astrocytes have been previously blocked suggests that spinal P2Y<sub>6,11</sub> receptors may participate promoting neuropathic pain at least partially in a microglia- or astrocytes-independent way. Supporting this, P2Y<sub>6</sub> but not P2Y<sub>11</sub> receptors mRNA have been found in dorsal root ganglion [26,40,41]. Taken together, data suggest that P2Y<sub>6,11</sub> receptors are present in microglia while P2Y<sub>11</sub> receptors are present only in astrocytes.

We found that repeated injections (for 7 days) of minocycline or fluorocitrate produced an antiallodynic effect in neuropathic rats. These data suggest that microglia and astrocytes play an important role in the maintenance phase of neuropathic pain. These data agree with previous observations showing that repeated treatment with minocycline reverses thermal hyperalgesia and mechanical allodynia [42-46]. In contrast, others have reported that minocycline prevents but do not reverses established neuropathic pain [47-49]. Differences could be due to the different models of neuropathic pain used. Regarding fluorocitrate, this drug reverses both ipsilateral and mirror-image spinal nerve injury-induced allodynia [49,50] which agree with our observations.

**Conclusion**

Our data suggest that spinal P2Y<sub>6,11</sub> receptors are present in spinal microglia while P2Y<sub>11</sub> receptors are present only in astrocytes. Both receptors are up-regulated in
rats subjected to spinal nerve injury. Our data suggest that the spinal P2Y6 and P2Y11 receptors participate in the maintenance of neuropathic pain.

**Methods**

**Animals**

Since previous experiments in our conditions found no differences between male and female rats [30], all experiments were performed on female Wistar rats (140–180 g). Animals were obtained from our own breeding facilities and had free access to food and drinking water. All experiments followed the Guidelines on Ethical Standards for Investigation of Experimental Pain in Animals [51] and the Mexican regulation (NOM-062-ZOO-1999). In addition, these experiments were approved by our local Ethics Committee (Protocol 455-09, Cinvestav, México City, México).

**Induction of spinal nerve ligation and measurement of tactile alldynia**

Rats were prepared according to the method of [52]. Briefly, animals were anesthetized with a mixture of ketamine (50 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.). After surgical preparation and exposure of the dorsal vertebral column, the left L5 and L6 spinal nerves were exposed and tightly ligated with 6-0 silk suture distal to the dorsal root ganglion. For sham-operated rats, the nerves were exposed but not ligated. Tactile allodynia was determined according to a previously reported method [53]. Fourteen days after surgery, rats were transferred to clear plastic, wire mesh-bottomed cages and allowed to acclimatize for 30–40 min. Von Frey filaments (Stoelting, Wood Dale, IL, USA) were used to determine the 50% paw withdrawal threshold using the up-down method [54]. Alldynia was considered to be present when paw withdrawal thresholds were less than 4 g.

**Spinal catheterization**

Chronic catheterization of the spinal subarachnoid space was performed as described [55]. Seven or nine days after spinal nerve injury, rats were again anesthetized with a ketamine (45 mg/kg, i.p.)/xylazine (12 mg/kg, i.p.) mixture, placed in a stereotaxic head holder, and the atlantooccipital membrane exposed. The membrane was pierced, and a polyethylene catheter (PE-10, 7.5 cm length) was inserted intrathecally and advanced caudally to the level of the thoracolumbar junction. Rats were allowed to recover from surgery for 5 days in individualized cages before drugs administration and testing. For spinal drug administration, rats received an intrathecal (i.t.) injection of vehicle (10 µl) or increasing concentrations of the P2Y6,11 receptor antagonists (µM/10 µl). The antiallodynic effect was evaluated for the following 6 h in both conditions.

**Drugs**

3-(2-Oxo-2-phenylethyl)-uridine-5’-diphosphate disodium salt (PSB0474), 4,4’-(carbonyl)bis(imino-3,1-phenylene-carboxyliminio)-3,1-(4-methyl phenylene)carboxyliminio)-bis (1,3-xylene-alpha, alpha’-diphosphoric acid tetrasodium salt (NF546), N,N’,1,4-butanediylbis[N-(3-isothiocyanatophenyl)thiourea (MRS2578) and 4,4’-(carbonyl)bis(imino-3,1-(4-methyl-phenylene)carboxyliminio))bis(naphthalene-2,6-disulfonic acid) tetrasodium salt (NF340) were purchased from Tocris Bioscience (Ellisville, MO). The purinergic drugs mentioned above were selected based on relevant receptor selectivity and efficacy. These included: (i) selective P2Y6 and P2Y11 receptors agonists PSB0474 [56] and NF546 [32], respectively, and (ii) selective P2Y6 and P2Y11 receptors antagonists MRS2578 [31] and NF340 [32], respectively. The doses used for P2Y6,11 receptor antagonists were chosen based in previous studies [28,32,57].

Minocycline hydrochloride (microglial inhibitor) and DL-fluorocitric acid barium salt (fluorocitrate, astrocytic inhibitor) were purchased from Sigma-Aldrich (St. Louis, MO). PSB0474, NF340 and NF546 were dissolved in 0.9% saline solution. MRS2578 and minocycline was dissolved in 20% DMSO. Fluorocitrate was dissolved initially in 2 M HCl (0.1 µmol/µL) and then diluted in 0.01 M PBS to attain a final concentration of 0.1 nmol/µL (pH 6.0). The vehicle control for fluorocitrate was 0.1% 2 M HCl in 0.01 M PBS (pH 6.0) [50].

**Western blot analysis**

Western blot analysis was used to detect changes in the expression of P2Y6,11 receptors as well as Iba-1 and GFAP protein levels in the lumbar ipsilateral and contralateral dorsal spinal cord. For this purpose, naïve and ligated rats were sacrificed by decapitation. The lumbar region of the spinal cord (L4–L6) was sectioned to get the ipsilateral section of the dorsal spinal cord. Immediately, tissues were stored at −70°C. Tissues from individual animals were homogenized in ice-cold lysis buffer (in mM: 150 NaCl, 50 Tris–HCl, 5 EDTA), pH 7.4 for 30 min at 4°C. The protease inhibitors PMSF (1 mM), aprotinin (10 µg/mL), leupeptin (10 µg/mL), pepstatin A (10 µg/mL) and the surfactant 0.1% Triton X-100 (Sigma-Aldrich, St. Louis, MO) were added to the lysis buffer immediately prior to use. The homogenate was then centrifuged (Eppendorf, Hamburg) at 14,000 rpm for 10 min to remove cellular debris. The resultant supernatant was used to measure protein concentration by the Bradford’s method (Bio–Rad, Hercules, CA).

Fifty (for Iba-1 and GFAP) or one hundred (for P2Y6 and P2Y11 receptors) µg of proteins were resolved by denaturing by 10% or 12% (for Iba-1) SDS–polyacrylamide gel electrophoresis and transferred to PVDF membranes. Membranes were incubated in 5% non-fat milk in phosphate-buffered saline (PBS) at pH 7.4 (in mM: 137 NaCl, 27 KCl, 10 Na2HPO4 and 2 KH2PO4) with 0.1% Tween 20 for 1 h to
block nonspecific proteins. After that, they were incubated overnight at 4°C in 5% non-fat dry milk/PBS containing rabbit anti-P2Y6 (BML-SA586-0050, 1:100, Enzo Life Sciences, Farmingdale, NY), rabbit anti-P2Y11 (AB9590, 1:500, Millipore, Billerica, MA), mouse anti-Iba-1 (MABN92, 1:500, Millipore, Billerica, MA) or rabbit anti-GFAP (AB5804, 1:1000, Millipore, Billerica, MA) antibodies. Membranes were incubated for 1 h at room temperature in 1% non-fat milk/PBS containing the horseradish peroxidase-conjugated secondary antibody (Donkey anti-rabbit, 711-035-152, 1:6000 or Donkey anti-mouse, 715-036-150, 1:5000; Both of Jackson immunoresearch, West Grove, PA). Protein signal detection was achieved with the ECL chemiluminescence system (ECL plus, Amersham, UK). The next day, blots were stripped and incubated with a monoclonal antibody directed against β-actin (1:10000, MAB1501R, Millipore, Billerica, MA) which was used as an internal control to normalize P2Y6 and P2Y11 receptors and Iba-1 and GFAP protein expression levels. Scanning of the immunoblots was performed and the bands were quantified by densitometry using an image analysis program (LabWorks; UVP Inc., Upland, CA). In addition, control peptides for P2Y6,11 receptors were tested to determine the bands specificity.

Experimental design
In order to determine the role of spinal P2Y6,11 receptors in the neuropathic pain induced by spinal nerve ligation, neuropathic animals (14 days later) were intrathecally administered with vehicle or increasing doses of the selective P2Y6 (MRS2578, 10–100 μM) and P2Y11 (NF340, 0.3–30 μM) receptor antagonists.

As selective P2Y6,11 receptor antagonists produced antiallodynic effects, we next determined the expression of these receptors at the ipsilateral and contralateral dorsal spinal cord at 1, 3, 7 and 14 days after injury. Furthermore, to confirm the participation of the spinal P2Y6,11 receptors in the processing of neuropathic pain in rats, the expression of these receptors in absence and presence of the selective P2Y6,11 receptor antagonists was determined. For this, we administered the P2Y6 (100 μM) and P2Y11 (30 μM) receptor antagonists every 12 h for 3 days starting on day 12 after ligation. Rats were sacrificed on day 14 after nerve ligation.

In order to investigate the role of microglia and astrocytes in spinal nerve injury-induced tactile allodynia, rats were ligated and intrathecally canulated. On day 14, these animals received a daily intrathecal injection of vehicle, minocycline (100 μg/day) or fluorocitrate (1 nmol/day) for seven days. Tactile allodynia was determined 24 h after the first administration and then every other day until day 21. Rats were sacrificed on day 21 to determine the protein expression of Iba-1 and GFAP in the ipsilateral and contralateral dorsal spinal cord.

As our data showed the participation of microglia and astrocytes in neuropathic pain induced by spinal nerve ligation, we next investigated the role of the spinal purinergic P2Y6,11 receptors in the same conditions. To further confirm the participation of glial cells and spinal P2Y6,11 receptors, we next evaluated the effect of selective P2Y6 (PSB0474, 3–30 μM) and P2Y11 (NF546, 1–10 μM) receptor agonists in rats previously treated with minocycline or fluorocitrate for 7 days.

Data analysis and statistics
All behavioral results are given as the mean ± S.E.M. for six animals per group. Curves were constructed by plotting the threshold for paw withdrawal as a function of time. An increase of 50% withdrawal threshold was considered as antiallodynia.

For protein expression, all results are given as the mean relative intensity ± S.E.M. for 3 animals per group. One- or two-way analysis of variance, followed by the Student-Newman-Keuls was used to compare differences between groups. Differences were considered to reach statistical significance when p < 0.05.

Additional files

Additional file 1: Figure S1. Spinal nerve injury enhances the expression of P2Y6,11 receptors at 21 days after injury. Western blot analysis of the P2Y6 and P2Y11 receptors expression in the ipsilateral dorsal spinal cord obtained 21 days after injury from naïve and spinal nerve injured rats. Data were normalized against β-actin and are expressed as the mean ± S.E.M. of 3 independent rats. *Significantly (p < 0.05) different from the naïve group, as determined by one-way analysis of variance followed by the Student-Newman-Keuls test.

Additional file 2: Figure S2. Full blots of the P2Y6 and P2Y11 protein expression in the contralateral dorsal spinal cord. Western blot analysis of the P2Y6 (panel A) and P2Y11 (panel B) receptors expression in the contralateral dorsal spinal cord obtained from naïve (N) and spinal nerve injured rats (SNL). Data were normalized against β-actin and are expressed as the mean ± S.E.M. of 3 independent rats.

Additional file 3: Figure S3. Intra- or intrathecal minocycline or fluorocitrate reduces tactile allodynia: Effects of P2Y6,11 receptor agonists. Effect of the intrathecal treatment with minocycline (green symbols) or fluorocitrate (purple symbols) in spinal nerve injured rats (panels A and B). Time course of the allodynic effect of PSB0474 and NF546 in rats previously treated with repeated intrathecal minocycline (panels A and B) or fluorocitrate (panels C and D), respectively. Data are expressed as mean ± S.E.M. for 6 animals. *Significantly (p < 0.05) different from the vehicle (veh) group, as determined by two-way analysis of variance followed by the Student-Newman-Keuls test.

Abbreviations
ADP: Adenosine diphosphate; ATP: Adenosine triphosphate; BDNF: Brain derived neurotrophic factor; CCL-2: Chemokine ligand 2; CCL-3: Chemokine ligand 3; GFAP: Giall fibrillary acidic protein; IL-1β: Interleukin-1β; IL-6: Interleukin-6; MRS2578: N'-1'-4-Butanediylbis(-3-isothiocyanatophenyl)methane; NF340: 4,4'-[Carbonylbis((imin-3-1-(4-methyl-phenylene)carboxylimino)bis)phosphorylthane-2,6-disulfonic acid tetrasodium salt; NF546: 4,4'-[Carbonylbis((imin-3-1-phenyleylene-carbonylimino)bis)bis(3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt; PBS: Phosphate-buffered saline; PSB0474: 3-(2-Oxo-2-phenylethyl)-uridine-5'-diphosphate disodium salt; TNFa: Tumor necrosis factor α; UDP: Uridine diphosphate.
Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
PB-I carried out the molecular and pharmacological studies, performed the statistical analysis and drafted the manuscript. JBP-F carried out the molecular studies. CC-D participated in the pharmacological studies. MB-H participated in the design and coordination of the study and helped to draft the manuscript. JM participated in the design, coordination and helped to draft to manuscript. VG-S conceived the idea, participated in the design and coordination of the study. He also helped to interpret the data and to draft the final manuscript. All authors read and approved the final manuscript.

Authors’ information
PB-I, JBP-F, CC-D and MB-H are graduate students at the Department of Pharmacobiology in Cinvestav, South Campus. Mexico City, Mexico. HIR-G is a full professor at the Department of Pharmacobiology in Cinvestav, South Campus. Mexico City, Mexico. JM is a full professor at the Department of Pharmacobiology in Cinvestav, South Campus. Mexico City, Mexico. VG-S is a full professor at the Department of Pharmacobiology in Cinvestav, South Campus. Mexico City, Mexico.

Acknowledgements
The authors gratefully appreciate the bibliographic assistance of B.S.C. Pilar Quinteros-Carrillo. Graduate students Paulino Barragán-Iglesias, Jorge B. Pineda-Farias, Claudia Cervantes-Durán and Mariana Bravo-Hernández are Conacyt fellows. Partially supported by Conacyt (grant CB-2012/179294 to VG-S). Pineda-Farias, Claudia Cervantes-Durán and Mariana Bravo-Hernández are Conacyt Quinteros-Carrillo. Graduate students Paulino Barragán-Iglesias, Jorge B. Pineda-Farias, Claudia Cervantes-Durán and Mariana Bravo-Hernández are Conacyt fellows. Partially supported by Conacyt (grant CB-2012/179294 to VG-S).

Author details
1Neurobiology of Pain Laboratory, Departamento de Farmacobiología, Centro de Investigación y de Estudios Avanzados (Cinvestav), Sede Sur, Calzada de los Tenorios 235, Colonia Granjas Coapa, 14330 México, D.F., México. 2Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, México D.F., México.

Received: 3 March 2014 Accepted: 10 May 2014

References
1. Chizh BA, Illes P: P2X receptors and nociception. Pharmacol Rev 2001, 53:553–568.
2. Wirkner K, Sperlagh B, Illes P: P2X5 receptor involvement in pain states. Mol Neurobiol 2007, 36:165–183.
3. Bleehen T, Keele CA: Observations on the algogenic actions of adenosine compounds on the human blister base preparation. Pain 1977, 3:367–377.
4. Hamilton SG, Warburton J, Bhattacharjee A, Warburton J, McMahon SB: Measurement of dorsal root ganglion P2X3 receptor expression and function following spinal nerve ligation in the rat. Exp Brain Res 2002, 147:511–519.
5. Okada M, Nakagawa T, Minami M, Satoh M: Dicyanate derivatives as potent, insurmountable antagonists of P2Y1 receptor, nucleotide receptors. Biochem Pharmacol 2004, 67:1763–1770.
6. Mes S, Hamacher A, Hongsitwe M, Marcianz C, Wiese M, Eckstein N, Royer HD, Communi D, Boezaerts JM, Hausmann R, Schmalzing G, Kassack MU: NF-κB [4,4′-(carbonyl-bis(imino-3,1-phenylene-carbonylimino-3,1-phenyl-1-methyl-phenylene)-car bonyl)]-bis(1,3-xylene-alpha, alpha'-dihydrophosphonic) acid tetrasodium salt is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. J Pharmacol Exp Therapeut 2010, 332:238–247.
7. Mamedova LK, Joshi BV, Gao ZG, von Kugelgen I, Jacobson KA: Disoctothiocynate derivatives as potent, insurmountable antagonists of P2Y12, nucleotide receptors. Biochem Pharmacol 2004, 67:1763–1770.

11. Sharp CI, Reeve AJ, Collins SD, Martindale JC, Summerfield SG, Sargent BS, Bate ST, Chessell IP: Investigation into the role of P2X2/P2X3 receptors in neuropathic pain following chronic constriction injury in the rat: an electrophysiological study. Br J Pharmacol 2006, 148:845–852.
12. Xiang Z, Xiong Y, Yan N, Li X, Mao J, Ni Y, X, He C, LaWotte RH, Burnstock G, Sun J: Functional up-regulation of P2X1 receptors in the chronically compressed dorsal root ganglion. Pain 2008, 140:23–34.
13. Zhang X, Chen Y, Wang C, Huang LY: Neuronal somatic ATP release triggers neuron-satellite gial cell communication in dorsal root ganglia. Proc Natl Acad Sci U S A 2007, 104:9864–9869.
14. Gosselin RD, Suter MR, Jr, RR, Decosterd I: Gial cells and chronic pain. Neuroscientist 2010, 16:519–531.
15. Kim C, Chung JM, Chung K: Changes in the gene expression of six subtypes of P2X receptors in rat dorsal root ganglion after spinal nerve ligation. Neurosci Lett 2003, 337:81–84.
16. Inoue K: The function of microglia through purinergic receptors: neuropathic pain and cytokine release. Pharmacol Ther 2006, 109:210–226.
17. North RA: Molecular physiology of P2X receptors. Physiol Rev 2002, 82:1013–1067.
18. Donnelly-Roberts D, Mcgarvautey S, Sheeh CC, Honore P, Jarvis M: Painful purinergic receptors. J Pharmacol Exp Therapeut 2008, 324:409–415.
19. Kobayashi K, Takahashi E, Miyagawa Y, Yamanaka H, Noguchi K: Induction of the P2X3 receptor in spinal microglia in a neuropathic pain model. Neurosci Lett 2011, 504:57–61.
20. Romero-Sandoval A, Chai N, Nutile-McMenemy N, Deleo JA: A comparison of spinal Iba1 and GFAP expression in rodent models of acute and chronic pain. Brain Res 2008, 1219:116–128.
21. Echeverry S, Shi XQ, Zhang J: Characterization of cell proliferation in rat spinal cord following peripheral nerve injury and the relationship with neuropathic pain. Pain 2008, 135:37–47.
22. Milligan ED, Watkins LR: Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2003, 102:36–34.
23. Inoue K, Tsuda M: Purinergic systems, neuropathic pain and the role of microglia. Exp Neurol 2012, 234:293–301.
24. Clark AK, Malcangio M: Microglial signalling mechanisms: Cathepsin S and Fractalkine. Exp Neurol 2012, 234:283–292.
25. Xiao HS, Huang QH, Zhang FX, Bao L, Lu YJ, Guo C, Yang L, Huang WJ, Fu G, Xu SH, Cheng XP, Yan Q, Zhu ZD, Zhang X, Chen Z, Han ZG, Zhang X: Identification of gene expression profile of dorsal root ganglion in the rat peripheral axotomy model of neuropathic pain. Proc Natl Acad Sci U S A 2002, 99:8360–8365.
26. Malin SA, Davis BM, Koerber HR, Reynolds U, Albers KM, Molliver DC: Thermal nociception and TRPV1 function are attenuated in mice lacking the nucleotide receptor P2Y12. Pain 2008, 138:484–496.
27. Tozaki-Saitoh H, Tsuda M, Miyata H, Ueda K, Kohnaka S, Inoue K: P2Y12 receptors in spinal microglia are required for neuropathic pain after peripheral nerve injury. J Neurosci 2008, 28:4940–4956.
28. Kobayashi K, Yamanaka H, Yano M, Okubo M, Noguchi K: Multiple P2Y subtypes in spinal microglia are involved in neuropathic pain after peripheral nerve injury. Glia 2012, 60:1529–1539.
29. Magni G, Cerruti S: P2Y purinergic receptors: new targets for analgesics and antinflammatory drugs. Biochem Pharmacol 2013, 85:466–477.
30. Caram-Salas NL, Reyes-Garcia G, Barragan-GK, Aranz-Saldana CL, Amritz-Tututi M, Rocha-González HI, Arreola-Espino R, Cruz SL, Granados-Soto V: Subcutaneous, intrathecal and periaqueductal grey administration of asimadoline and ICI-204448 reduces tactile allodynia in the rat. Eur J Pharmacol 2007, 575:75–83.
31. Mamedova LK, Joshi BV, Gao ZG, von Kugelgen I, Jacobson KA: Dicyanate derivatives as potent, insurmountable antagonists of P2Y12, nucleotide receptors. Biochem Pharmacol 2004, 67:1763–1770.
32. Mes S, Hamacher A, Hongsitwe M, Marcianz C, Wiese M, Eckstein N, Royer HD, Communi D, Boezaerts JM, Hausmann R, Schmalzing G, Kassack MU: NF-κB [4,4′-(carbonyl-bis(imino-3,1-phenylene-carbonylimino-3,1-phenyl-1-methyl-phenylene)-car bonyl)]-bis(1,3-xylene-alpha, alpha'-dihydrophosphonic) acid tetrasodium salt is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. J Pharmacol Exp Therapeut 2010, 332:238–247.
Barragán-Iglesias et al. Molecular Pain 2014, 10:29
http://www.molecularpain.com/content/10/1/29

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

34. Fricks P, Maddileti S, Carter RL, Lazarski ER, Nicholas RA, Jacobson KA, Harden TK. UDP is a competitive antagonist at the human P2Y_{14} receptor. J Pharmacol Exp Therapeut 2008, 325:588–594.
35. Kobayashi K, Fukuda T, Yamakata H, Dai Y, Obata K, Tokunaga A, Noguchi R. Neurons and glial cells differentially express P2Y receptor mRNAs in the rat dorsal root ganglion and spinal cord. J Comp Neurol 2006, 498:43–454.
36. Yu J, Sheung N, Soliman EM, Speli C, Dranoff IA. Transcriptional regulation of IL-6 in bile duct epithelia by extracellular ATP. Am J Physiol Gastrointest Liver Physiol 2009, 296:G563–G571.
37. Brandenburg LO, Jansen S, Wurck CJ, Lucius R, Paule T. Antimicrobial peptide CRAMP induced glial cell activation through P2Y receptor signalling pathways. Mol Immunol 2010, 47:1905–1913.
38. Ohtomo K, Satoas MA, Vouvalis L, Li D, Hodges RR, Darrr DA. Increase of intracellular Ca^{2+} by purinergic receptors in cultured rat lacrimal gland myoepithelial cells. Invest Ophthalmol Vis Sci 2011, 52:9503–9515.
39. Alkayed F, Kashimata M, Koyama N, Hayashi T, Tamura Y, Azuma Y. P2Y_{11} purinoceptor mediates the ATP-enhanced chemotactic response of rat neutrophils. J Pharmacol Sci 2012, 120:286–295.
40. Sanada M, Yasuda H, Oomatsu-Kanbe M, Sango K, Isono T, Matsuura H, Kikkawa K. A minocycline derivative reduces nerve injury-induced pain in rat. J Comp Neurol 2009, 515:1141–1142.
41. Ruan HZ, Burnstock G. Localisation of P2Y_{2} and P2Y_{4} receptors in dorsal root, nodose and trigeminal ganglia of the rat. Histochem Cell Biol 2003, 120:415–426.
42. LeBlanc BC, Zerah ML, Kadasa LM, Chai N, Saab CY. Minocycline injection in the ventral posterolateral thalamus reverses microglial reactivity and thermal hyperalgesia secondary to sciatric neuropathy. Neurosci Lett 2011, 498:138–142.
43. Mika J, Osikowicz M, Przewlocka B. Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. Eur J Pharmacol 2007, 560:142–149.
44. Mei XP, Xu H, Cie X, Ren J, Zhou Y, Zhang H, Xu LX. Post-injury administration of minocycline: an effective treatment for nerve-injury induced neuropathic pain. Neurosci Res 2011, 70:305–312.
45. Nazemi S, Manaeji H, Zarzouhali M, Sadeghi M, Hayghanparast A. Post-injury repeated administrations of minocycline improve the antinociceptive effect of morphine in chronic constriction injury model of neuropathic pain in rat. Pharmacol Biochem Behav 2012, 102:520–525.
46. Bastos LF, Godin AM, Zhang Y, Jurasophon S, Ferreira BC, Machado RR, Maier SF, Konishi Y, de Freitas RP, Fiebich BL, Watkins LR, Coelho MM, Martins MF. A minocycline derivative reduces nerve injury-induced allodynia, LPS-induced prostaglandin E2 microglial production and signaling via toll-like receptors 2 and 4. Neurosci Lett 2013, 543:157–162.
47. Raghavendra V, Tanga F, DeLeo JA. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Therapeut 2003, 306:624–630.
48. Padi SS, Kulkarni SK. Minocycline prevents the development of neuropathic pain, but not acute pain: possible anti-inflammatory and antioxidant mechanisms. Eur J Pharmacol 2008, 601:79–87.
49. Zhang X, Xu Y, Wang J, Zhou Q, Pu S, Jiang W, Du D. The effect of intrathecal administration of glial activation inhibitors on dorsal horn BDNF overexpression and hind paw mechanical allodynia in spinal nerve ligated rats. J Neural Transm 2013, 119:229–336.
50. Milligan ED, Twining C, Chaur M, Biedenkapp J, O’Connor K, Poole S, Tracy K, Martin D, Maier SF, Watkins LR. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci 2003, 23:1026–1040.
51. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109–110.
52. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992, 50:335–343.
53. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yakhsh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994, 53:55–63.
54. Dixon WJ. Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 1980, 20:441–462.
55. Yaksh TL, Rudy TA. Chronic catheterization of the spinal subarachnoid space. Physiol Behav 1976, 17:1031–1036.
56. El-Tayeb A, Qi A, Muller CE. Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y_{2}, P2Y_{4}, and P2Y_{11} receptors. J Med Chem 2006, 49:7076–7087.